Addex Therapeutics (Switzerland) Performance
| ADXN Stock | CHF 0.06 0.0008 1.38% |
On a scale of 0 to 100, Addex Therapeutics holds a performance score of 3. The firm shows a Beta (market volatility) of -0.39, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Addex Therapeutics are expected to decrease at a much lower rate. During the bear market, Addex Therapeutics is likely to outperform the market. Please check Addex Therapeutics' downside deviation, standard deviation, and the relationship between the semi deviation and coefficient of variation , to make a quick decision on whether Addex Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Addex Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Addex Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 18.7 M | |
| Total Cashflows From Investing Activities | -30.3 K |
Addex |
Addex Therapeutics Relative Risk vs. Return Landscape
If you would invest 5.50 in Addex Therapeutics on December 24, 2024 and sell it today you would earn a total of 0.20 from holding Addex Therapeutics or generate 3.64% return on investment over 90 days. Addex Therapeutics is generating 0.2272% of daily returns and assumes 5.9378% volatility on return distribution over the 90 days horizon. Simply put, 53% of stocks are less volatile than Addex, and 96% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Addex Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Addex Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Addex Therapeutics, and traders can use it to determine the average amount a Addex Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0383
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ADXN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.94 actual daily | 53 53% of assets are less volatile |
Expected Return
| 0.23 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Addex Therapeutics is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Addex Therapeutics by adding it to a well-diversified portfolio.
Addex Therapeutics Fundamentals Growth
Addex Stock prices reflect investors' perceptions of the future prospects and financial health of Addex Therapeutics, and Addex Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Addex Stock performance.
| Return On Equity | -2.03 | |||
| Return On Asset | -0.88 | |||
| Operating Margin | (17.07) % | |||
| Current Valuation | 2.92 M | |||
| Shares Outstanding | 115.35 M | |||
| Price To Earning | 39.53 X | |||
| Price To Book | 1.62 X | |||
| Price To Sales | 9.82 X | |||
| Revenue | 2.92 M | |||
| EBITDA | (14.94 M) | |||
| Cash And Equivalents | 20.48 M | |||
| Cash Per Share | 1.58 X | |||
| Total Debt | 194.32 K | |||
| Book Value Per Share | 0.15 X | |||
| Cash Flow From Operations | (14.71 M) | |||
| Earnings Per Share | (0.53) X | |||
| Total Asset | 22.54 M | |||
About Addex Therapeutics Performance
Evaluating Addex Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Addex Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Addex Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system disorders in Switzerland. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Plan-les-Ouates, Switzerland. ADDEX N operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 17 people.Things to note about Addex Therapeutics performance evaluation
Checking the ongoing alerts about Addex Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Addex Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Addex Therapeutics had very high historical volatility over the last 90 days | |
| Addex Therapeutics has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 2.92 M. Net Loss for the year was (15.35 M) with loss before overhead, payroll, taxes, and interest of (9.69 M). | |
| Addex Therapeutics has accumulated about 20.48 M in cash with (14.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.58, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Addex Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Addex Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Addex Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Addex Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Addex Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Addex Therapeutics' stock. These opinions can provide insight into Addex Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Addex Stock Analysis
When running Addex Therapeutics' price analysis, check to measure Addex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Addex Therapeutics is operating at the current time. Most of Addex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Addex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Addex Therapeutics' price. Additionally, you may evaluate how the addition of Addex Therapeutics to your portfolios can decrease your overall portfolio volatility.